2-fluoro-4-isocyanatopyridine | 1260664-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-fluoro-4-isocyanatopyridine
• CAS: 1260664-63-8
• 化学式: C₆H₃FN₂O
• 分子量: 138.101
• InChiKey: GSCOAZZIWURTHX-UHFFFAOYSA-N

物化性质

• 沸点：
  212.1±25.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-fluoro-4-isocyanatopyridine 、 (1,4-Dimethylpyrazolo[3,4-b]pyridin-6-yl)hydrazine 以 四氢呋喃 为溶剂， 生成 1-[(1,4-Dimethylpyrazolo[3,4-b]pyridin-6-yl)amino]-3-(2-fluoropyridin-4-yl)urea
  参考文献：
  名称：

  S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer

  摘要：

  In this study, S1PR2 was reckoned as a brand-new GPCR target for designing inhibitors to reverse 5-FU resistance. Herein a series of pyrrolidine pyrazoles as the S1PR2 inhibitors were designed, synthesized and evaluated for their activities of anti-FU-resistance. Among them, the most promising compound JTE-013, exhibited excellent inhibition on DPD expression and potent anti-FU-resistance activity in various human cancer cell lines, along with the in vivo HCT116(DPD) cells xenograft model, in which the inhibition rate of 5-FU was greatly increased from 13.01%-75.87%. The underlying mechanism was uncovered that JTE-013 demonstrated an anti-FU-resistance activity by blocking S1PR2 internalization to the endoplasmic reticulum (ER), which inhibited the degradation of 5-FU into alpha-fluoro-beta-alanine (FBAL) by downregulating tumoral DPD expression. Overall, JTE-013 could serve as the lead compound for the discovery of new anti-FU-resistance drugs.Significance: This study provides novel insights that S1PR2 inhibitors could sensitize 5-FU therapy in colorectal cancer.

  DOI：

  10.1016/j.phrs.2020.104717
• 作为产物：
  描述：

  2-氟异烟酸 在 sodium azide 、 草酰氯 作用下， 以 DMF (N,N-dimethyl-formamide) 、 乙酸乙酯 、 甲苯 为溶剂， 反应 3.0h， 生成 2-fluoro-4-isocyanatopyridine
  参考文献：
  名称：

  N-PHENYL-(2R,5S)DIMETHYLPIPERAZINE DERIVATIVE

  摘要：

  公开号：

  EP1557411B1

文献信息

• N-phenyl-(2r,5s) dimethylpiperadine derivative
  申请人：Taniguchi Nobuaki

  公开号：US20050261303A1

  公开（公告）日：2005-11-24

  The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and the like. The present invention also provides a novel intermediate useful in producing the compound of the present invention.

  本发明涉及一种新型的N-苯基-(2R,5S)二甲基哌嗪衍生物，其作为抗雄激素剂具有足够的前列腺减少效果，与传统化合物相比具有出色的口服活性。本申请的化合物可用于预防或治疗前列腺癌、良性前列腺增生等疾病。本发明还提供了一种用于制备本发明化合物的新型中间体。
• N-Phenyl-(2R,5S)Dimethylpiperazine Derivative
  申请人：Taniguchi Nobuaki

  公开号：US20080214543A1

  公开（公告）日：2008-09-04

  The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and the like. The present invention also provides a novel intermediate useful in producing the compound of the present invention.

  本发明涉及一种新型N-苯基-(2R,5S)二甲基哌嗪衍生物，其作为抗雄激素剂具有足够的前列腺减少效果，与传统化合物相比具有出色的口服活性。本申请的化合物在预防或治疗前列腺癌、良性前列腺增生等方面具有用途。本发明还提供了一种新型中间体，用于制备本发明的化合物。
• Phenyl and pyridyl compounds for inflammation and immune-related uses
  申请人：Jiang Jun

  公开号：US20070275960A1

  公开（公告）日：2007-11-29

  The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R 1 , X 1 , X 2 , Y, Z, L, and n are defined herein. The compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

  本发明涉及结构式（I）的化合物：或其药学上可接受的盐，溶剂化合物，包合物或前药，其中R1，X1，X2，Y，Z，L和n在此定义。这些化合物可用作免疫抑制剂，并用于治疗和预防炎症病症，过敏性疾病和免疫疾病。
• N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1557411A1

  公开（公告）日：2005-07-27

  The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and the like. The present invention also provides a novel intermediate useful in producing the compound of the present invention.

  本发明涉及一种新型 N-苯基-(2R,5S)二甲基哌嗪衍生物，可用作抗雄激素制剂，与传统化合物相比，该衍生物具有足够的前列腺抑制作用，且口服活性极佳。本申请的化合物可用于预防或治疗前列腺癌、良性前列腺增生症等。本发明还提供了一种可用于生产本发明化合物的新型中间体。
• N-PHENYL-(2R,5S)DIMETHYLPIPERAZINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP1557411B1

  公开（公告）日：2012-10-17